AC Immune SA (ACIU): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACIU POWR Grades
- ACIU scores best on the Sentiment dimension, with a Sentiment rank ahead of 97.96% of US stocks.
- The strongest trend for ACIU is in Momentum, which has been heading up over the past 151 days.
- ACIU ranks lowest in Quality; there it ranks in the 8th percentile.
ACIU Stock Summary
- Of note is the ratio of AC IMMUNE SA's sales and general administrative expense to its total operating expenses; merely 8.79% of US stocks have a lower such ratio.
- With a price/sales ratio of 42.29, AC IMMUNE SA has a higher such ratio than 96.01% of stocks in our set.
- ACIU's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 8.09% of US stocks.
- If you're looking for stocks that are quantitatively similar to AC IMMUNE SA, a group of peers worth examining would be STTK, GRNA, IVA, GOVX, and AUTL.
- ACIU's SEC filings can be seen here. And to visit AC IMMUNE SA's official web site, go to www.acimmune.com.
ACIU Price Target
For more insight on analysts targets of ACIU, see our ACIU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $15.23 | Average Broker Recommendation | 1.17 (Strong Buy) |
ACIU Stock Price Chart Interactive Chart >
ACIU Price/Volume Stats
| Current price | $2.19 | 52-week high | $4.84 |
| Prev. close | $2.14 | 52-week low | $1.68 |
| Day low | $2.04 | Volume | 1,018,000 |
| Day high | $2.20 | Avg. volume | 174,523 |
| 50-day MA | $2.33 | Dividend yield | N/A |
| 200-day MA | $2.74 | Market Cap | 182.98M |
AC Immune SA (ACIU) Company Bio
AC Immune SA, a clinical stage Swiss-based biopharmaceutical company, focuses on neurodegenerative diseases with three product candidates in clinical trials. It designs, discovers, and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by mis-folding proteins. The company was founded in 2003 and is based in Lausanne, Switzerland.
Latest ACIU News From Around the Web
Below are the latest news stories about AC IMMUNE SA that investors may wish to consider to help them evaluate ACIU as an investment opportunity.
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine PipelineAC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline Ten presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM)AC Immune’s Chief Medical Officer to participate in expert forum on immunotherapies in Alzheimer’s disease Lausanne, Switzerland, March 20, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced |
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate UpdateAC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023ACI-24.060 anti-amyloid-beta vaccine for Alzheimer’s disease (AD) showed positive initial safety and immunogenicity in Phase 1b/2 ABATE trial; further interim data expected in H2 2023; first amyloid plaque PET imaging results anticipated in 2024A |
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 Lausanne, Switzerland, March 8, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will issue a press release to report its full year 2022 financial results and provide a corporate update on March 16, 2023 at 7:00am ET. Thereafter, Company management will be available for one-on-one ca |
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 The Michael J. Fox Foundation grant supports the development of AC Immune’s first-in-class TDP-43 PET tracer programTarget ALS Foundation grant supports collaboration between AC Immune and world-class institutions to accelerate the development of novel biofluid assays for detecting TDP-43-related neuropathology Lausanne, Switzerland, February 7, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharm |
AC Immune to Present at the SVB Securities Global Biopharma ConferenceAC Immune to Present at the SVB Securities Global Biopharma Conference Lausanne, Switzerland, February 2, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the SVB Securities Global Biopharma Conference, which is taking place virtually from February 14 – 16, 2023. During the fireside chat, AC |
ACIU Price Returns
| 1-mo | -6.01% |
| 3-mo | 25.50% |
| 6-mo | -8.75% |
| 1-year | -50.45% |
| 3-year | -62.24% |
| 5-year | -80.72% |
| YTD | 7.35% |
| 2022 | -58.79% |
| 2021 | -4.26% |
| 2020 | -39.32% |
| 2019 | -9.84% |
| 2018 | -26.17% |
Continue Researching ACIU
Want to see what other sources are saying about AC Immune SA's financials and stock price? Try the links below:AC Immune SA (ACIU) Stock Price | Nasdaq
AC Immune SA (ACIU) Stock Quote, History and News - Yahoo Finance
AC Immune SA (ACIU) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...